Thrombosis and Hyperinflammation in COVID-19 Acute Phase Are Related to Anti-Phosphatidylserine and Anti-Phosphatidylinositol Antibody Positivity
Alijotas-Reig, Jaume (Universitat Autònoma de Barcelona. Departament de Medicina)
Anunciación-Llunell, Ariadna (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Morales-Pérez, Stephanie (Fundació Althaia)
Trapé, Jaume (Fundació Althaia)
Esteve-Valverde, Enrique (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT))
Miró-Mur, Francesc (Hospital Universitari Vall d'Hebron. Institut de Recerca)

Date:	2023
Abstract:	Antiphospholipid antibodies (APLA) are strongly associated with thrombosis seen in patients with antiphospholipid syndrome. In COVID-19, thrombosis has been observed as one of the main comorbidities. In patients hospitalised for COVID-19, we want to check whether APLA positivity is associated with COVID-19-related thrombosis, inflammation, severity of disease, or long COVID-19. We enrolled 92 hospitalised patients with COVID-19 between March and April 2020 who were tested for 18 different APLAs (IgG and IgM) with a single line-immunoassay test. A total of 30 healthy blood donors were used to set the cut-off for each APLA positivity. Of the 92 COVID-19 inpatients, 30 (32. 61%; 95% CI [23. 41-43. 29]) tested positive for APLA, of whom 10 (33. 3%; 95% CI [17. 94-52. 86]) had more than one APLA positivity. Anti-phosphatidylserine IgM positivity was described in 5. 4% of inpatients (n = 5) and was associated with the occurrence of COVID-19-related thrombosis (p = 0. 046). Anti-cardiolipin IgM positivity was the most prevalent among the inpatients (n = 12, 13. 0%) and was associated with a recorded thrombosis in their clinical history (p = 0. 044); however, its positivity was not associated with the occurrence of thrombosis during their hospitalisation for COVID-19. Anti-phosphatidylinositol IgM positivity, with a prevalence of 5. 4% (n = 5), was associated with higher levels of interleukin (IL)-6 (p = 0. 007) and ferritin (p = 0. 034). Neither of these APLA positivities was a risk factor for COVID-19 severity or a predictive marker for long COVID-19. In conclusion, almost a third of COVID-19 inpatients tested positive for at least one APLA. Anti-phosphatidylserine positivity in IgM class was associated with thrombosis, and anti-phosphatidylinositol positivity in IgM class was associated with inflammation, as noticed by elevated levels of IL-6. Thus, testing for non-criteria APLA to assess the risk of clinical complications in hospitalised COVID-19 patients might be beneficial. However, they were not related to disease severity or long COVID-19.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Antiphospholipid antibodies ; Anti-phosphatidylserine antibody ; Anti-phosphatidylinositol antibody ; COVID-19 ; Disease severity ; Long COVID-19 ; Thrombosis
Published in:	Biomedicines, Vol. 11 (august 2023) , ISSN 2227-9059

DOI: 10.3390/biomedicines11082301
PMID: 37626797

16 p, 2.5 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Parc Taulí Research and Innovation Institute (I3PT
Articles > Research articles
Articles > Published articles